GURUFOCUS.COM » STOCK LIST » USA » NAS » Compass Therapeutics Inc (NAS:CMPX) » Definitions » Financial Strength
Switch to:

Compass Therapeutics (NAS:CMPX) Financial Strength

: 8 (As of Jun. 2023)
View and export this data going back to 2020. Start your Free Trial

Compass Therapeutics has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Compass Therapeutics Inc shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Compass Therapeutics's interest coverage with the available data. As of today, Compass Therapeutics's Altman Z-Score is 0.00.


Competitive Comparison

For the Biotechnology subindustry, Compass Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Compass Therapeutics Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Financial Strength distribution charts can be found below:

* The bar in red indicates where Compass Therapeutics's Financial Strength falls in comparison to its industry or sector. The grey bar indicates the Financial Strength's extreme value range as defined by GuruFocus.



Compass Therapeutics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Compass Therapeutics's Interest Expense for the months ended in Jun. 2023 was $0.00 Mil. Its Operating Income for the months ended in Jun. 2023 was $-13.34 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $1.20 Mil.

Compass Therapeutics's Interest Coverage for the quarter that ended in Jun. 2023 is

GuruFocus does not calculate Compass Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Compass Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Compass Therapeutics's Debt to Revenue Ratio for the quarter that ended in Jun. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.147 + 1.197) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Compass Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Compass Therapeutics  (NAS:CMPX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Compass Therapeutics has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.


Compass Therapeutics Financial Strength Related Terms

Thank you for viewing the detailed overview of Compass Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Therapeutics (NAS:CMPX) Business Description

Compass Therapeutics logo
Traded in Other Exchanges
N/A
Address
80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.
Executives
Richard S Lindahl director NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
David M Wurzer director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Ellen Chiniara director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Philip Ferneau director 10 ALLEN STREET, HANOVER NH 03755
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp V Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Susan Kalled officer: Chief Scientific Officer COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135
Brett Kaplan director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Stephen P Squinto director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Thomas J. Schuetz director, officer: Chief Executive Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063